DBV Technologies

DBV Technologies’ candidate could be the first treatment for allergies to cow milk after its Viaskin Milk skin patch achieved positive Phase II results. DBV Technologies is developing a skin patch, Viaskin, as an immunotherapy for the treatment peanut, egg, and milk allergies. In a Phase II study, Viaskin Milk has desensitized children between the […]

DBV Technologies has positive safety data supporting the approval of a treatment for peanut allergy in children, though its efficacy is uncertain. DBV Technologies saw its stock go down by 45% last month after releasing Phase III data for ViaSkin Peanut, a treatment delivered via a skin patch aimed at reducing peanut allergy in children aged […]

DBV Technologies plans to go ahead with its peanut allergy treatment despite its failure to meet a primary endpoint in Phase III. Last Friday, DBV Technologies released the results of a Phase III trial that was key to the approval of a treatment to reduce peanut allergy in children. After 12 months, 35% of children […]

The first French biotech to NASDAQ, DBV, is expanding the patient group for its promising peanut allergy treatment to include toddlers. DBV Technologies’ Phase IIb results of its peanut allergy therapy, Viaskin Peanut, were one of 2016’s biggest clinical success stories when it successfully desensitized children to obviate life-threatening allergies. A trial in children between the ages […]